JPH0460582B2 - - Google Patents

Info

Publication number
JPH0460582B2
JPH0460582B2 JP63302127A JP30212788A JPH0460582B2 JP H0460582 B2 JPH0460582 B2 JP H0460582B2 JP 63302127 A JP63302127 A JP 63302127A JP 30212788 A JP30212788 A JP 30212788A JP H0460582 B2 JPH0460582 B2 JP H0460582B2
Authority
JP
Japan
Prior art keywords
formula
compound
pharmaceutically acceptable
salts
thiazolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP63302127A
Other languages
English (en)
Japanese (ja)
Other versions
JPH01186883A (ja
Inventor
Nooman Kuratsupu Maikuru
Karuhon Suinderu Aachi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Original Assignee
PFIZER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER filed Critical PFIZER
Publication of JPH01186883A publication Critical patent/JPH01186883A/ja
Publication of JPH0460582B2 publication Critical patent/JPH0460582B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP63302127A 1987-12-02 1988-11-29 抗アテローム性動脈硬化症剤としてのｄｌ‐５‐〔（２ベンジル‐３，４‐ジヒドロ‐２Ｈ‐ベンゾピラン‐６‐イル）メチル〕チアゾリジン‐２，４‐ジオン Granted JPH01186883A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US127858 1987-12-02
US07/127,858 US4798835A (en) 1987-12-02 1987-12-02 dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent

Publications (2)

Publication Number Publication Date
JPH01186883A JPH01186883A (ja) 1989-07-26
JPH0460582B2 true JPH0460582B2 (de) 1992-09-28

Family

ID=22432331

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63302127A Granted JPH01186883A (ja) 1987-12-02 1988-11-29 抗アテローム性動脈硬化症剤としてのｄｌ‐５‐〔（２ベンジル‐３，４‐ジヒドロ‐２Ｈ‐ベンゾピラン‐６‐イル）メチル〕チアゾリジン‐２，４‐ジオン

Country Status (16)

Country Link
US (1) US4798835A (de)
EP (1) EP0319288B1 (de)
JP (1) JPH01186883A (de)
KR (1) KR900006993B1 (de)
AT (1) ATE81456T1 (de)
AU (1) AU604176B2 (de)
CA (1) CA1313139C (de)
DE (1) DE3875324T2 (de)
DK (1) DK670988A (de)
HU (1) HU204433B (de)
IE (1) IE883600L (de)
IL (1) IL88513A (de)
MY (1) MY103498A (de)
PH (1) PH24873A (de)
PT (1) PT89123B (de)
ZA (1) ZA888968B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053420A (en) * 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
ES2092539T3 (es) * 1991-01-10 1996-12-01 Transcend Therapeutics Inc Uso de derivados de la tiazolidina-4-carboxilato para el tratamiento de enfermedades pulmonares.
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
US5866595A (en) * 1991-09-26 1999-02-02 The Regents Of The University Of California Calcium antagonists for treatment of vascular restenosis
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
US5306724A (en) * 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
US5447712A (en) * 1993-12-09 1995-09-05 Free Radical Sciences Method of reducing cyclophosphamide induced hemorrhagic cystitis
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
US4617312A (en) * 1983-01-17 1986-10-14 Pfizer Inc. Aldose reductase inhibiting 5-(2-alkoxyphenyl) thiazolidinediones
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物

Also Published As

Publication number Publication date
ATE81456T1 (de) 1992-10-15
IL88513A0 (en) 1989-06-30
PT89123A (pt) 1989-12-29
IE883600L (en) 1989-06-02
US4798835A (en) 1989-01-17
DE3875324T2 (de) 1993-02-25
AU604176B2 (en) 1990-12-06
HUT54045A (en) 1991-01-28
AU2647188A (en) 1989-06-08
CA1313139C (en) 1993-01-26
PT89123B (pt) 1993-09-30
DK670988D0 (da) 1988-12-01
EP0319288A3 (en) 1990-12-27
JPH01186883A (ja) 1989-07-26
ZA888968B (en) 1990-07-25
DK670988A (da) 1989-07-24
DE3875324D1 (de) 1992-11-19
EP0319288A2 (de) 1989-06-07
PH24873A (en) 1990-12-26
IL88513A (en) 1994-04-12
MY103498A (en) 1993-06-30
EP0319288B1 (de) 1992-10-14
HU204433B (en) 1992-01-28
KR900006993B1 (ko) 1990-09-25
KR890009922A (ko) 1989-08-04

Similar Documents

Publication Publication Date Title
US20140303217A1 (en) Dosing regimen for a selective s1p1 receptor agonist
JP2001500883A (ja) 低脂質値のためのシブトラミン類似物の使用
JPH01299289A (ja) 血糖降下剤としてのチアゾリジンジオン誘導体
FR2590170A1 (fr) Agents therapeutiques a base de sel d'acyloxyalcanoylcholine, apportant une amelioration dans le traitement de la demence
DE69434198T2 (de) Verfahren zur senkung des serumcholesterinspiegels mit 2,6-dialkyl-4 silyl-phenol derivaten
CH630068A5 (en) Process for the preparation of 4-hydroxyphenylalkanolamine derivatives
JPH0460582B2 (de)
MC1878A1 (fr) Compositions pharmaceutiques
BE1009060A3 (fr) Compositions pharmaceutiques et procede permettant leur preparation.
FR2666741A1 (fr) Composition therapeutique pour inhiber l'agregation plaquettaire.
CN1103783A (zh) 降低血脂水平的药物
EP0469837B1 (de) Verwendung einer Verbindung zur Herstellung eines Arzneimittels zur Senkung des Harnsäuregehalts des Blutes
JPH0813741B2 (ja) 抗痴呆剤
HUP0203790A2 (hu) (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére
JP3357378B2 (ja) 糖尿病処置用のオキシランカルボン酸
EA003055B1 (ru) Способ лечения легочной гипертензии
JPH05503510A (ja) 光学的に純粋な（ｓ）―アテノロールを含む組成物と方法
JPH05194220A (ja) 高血圧症治療用の組成物及び方法
LU85371A1 (fr) Procede de traitement antiarythmique de classe iii
JPH0653678B2 (ja) アレルギ−性疾患治療剤
CN101068548A (zh) 用于减少、稳定富含脂质的斑块和/或防止富含脂质的斑块破裂的方法
JPH07133225A (ja) 毛様体筋緊張緩和剤
JPH08183734A (ja) 内毒素ショックの処置へのカルニチンおよびアルカノイルカルニチン類のフタリジリデンエステル類の使用
JPS63107925A (ja) 動脈硬化症予防・治療剤
MC2019A1 (fr) Composition pharmaceutique anti-hypertensive combinee